News Release

SAN DIEGO, Apr 24, 2012 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) today announced the availability of its
MyGenome application for the iPad, available for download on the App
Store(SM) for 99 cents. Illumina's MyGenome app empowers
users to explore a real human genome and view reports about important
genetic variations through a simple, intuitive, and educational
interface for genetic data exploration and learning.

"Illumina's vision of a future where healthcare is made more precise
through the use of genetic information, together with our position as a
sequencing technology leader, puts us in an ideal position to stimulate
interest in a mainstream tool for genomic exploration," said Jay
Flatley, Illumina's President and CEO. "The MyGenome app is an exciting
educational tool that enables consumers to learn how much we already
understand about variation in the human genome, served up in a
graphically accessible format. This first version of the app provides a
glimpse of what we think could become a clinical tool for use by
physicians with their patients to improve understanding and
communication of genetic data."

Key features of the MyGenome app include:

Genome Map - for touring the landscape of chromosomes and
visualizing how genetic variants in different locations translate into
health impacts or biological traits. Users can view individual genes,
their locations, and biological impacts, as well as visualize where
and how genome sequences differ from the "reference" human genome.
Illumina's Flatley donated his genome as the first example of a
consumer genome that is compared to the reference genome for
educational purposes.

Health Cards - for exploring genetically determined conditions
and predispositions, and carrier traits. Users can discover how
different genetic variants can contribute to health risks and can be
passed on to children, as well as find out how changes in the genome
may affect drug response.

Reports - for investigating the possible health impacts of
genetic variants for more than 250 conditions. These reports
illustrate how genetic information will likely be delivered in the
future and used by medical professionals to interpret and understand
the human genome.

As new genomic discoveries occur, or as more becomes known about
existing conditions, updates to the application will contain and "flag"
those new pieces of information - making the MyGenome app an
ever-evolving tool.

Future versions of the MyGenome app also will enable the download of
consumer data in a secure fashion. Specifically, as part of its Individual
Genome Sequencing (IGS) service in the CLIA-certified laboratory,
Illumina plans to deliver genetic data to the ordering physician via the
MyGenome app. The physician will access a consumer's genomic information
from the app, allowing them to visualize the genome and interrogate it
for issues such as Mendelian disorders and pharmacogenomic drug
response, before providing direct access to the consumer.

Further, at Illumina's Understand Your Genome event in October, invitees
from the healthcare industry will have the opportunity to view their own
genetic information using the MyGenome app, after being sequenced
through the IGS service with an order from their physician. Illumina
will use feedback from consumers as well as these healthcare industry
participants to further guide the tool's evolution.

Illumina (www.illumina.com)
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.